Survival Outcomes with Regorafenib and/or Trifluridine/Tipiracil Sequencing to Rechallenge with Third-Line Regimens in Metastatic Colorectal Cancer: A Multicenter Retrospective Real-World Subgroup Comparison from the ReTrITA Study

This study suggests that rechallenge therapy may improve survival rates in the third-line treatment of mCRC, particularly if it is administered before sequential R/T treatment. This could allow for the extension of mCRC treatment choices until prospective studies are finished or randomised trials are performed.

Authors

Institutions

Publication Details

Journal
Current Oncology
Published
2024-12-04
DOI
https://doi.org/10.3390/curroncol31120574
Citations
2
Primary Topic
Colorectal Cancer Treatments and Studies
Type
article
Field-Weighted Citation Impact
0.57
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Survival Outcomes with Regorafenib and/or Trifluridine/Tipiracil Sequencing to Rechallenge with Third-Line Regimens in Metastatic Colorectal Cancer: A Multicenter Retrospective Real-World Subgroup Comparison from the ReTrITA Study

Emanuela Dell’Aquila, Manuela Dettori, Michele A. Basso, Federica Mazzuca et al.
2 citations
Current Oncology
Colorectal Cancer Treatments and Studies
0.57
article

Survival Outcomes with Regorafenib and/or Trifluridine/Tipiracil Sequencing to Rechallenge with Third-Line Regimens in Metastatic Colorectal Cancer: A Multicenter Retrospective Real-World Subgroup Comparison from the ReTrITA Study

Emanuela Dell’Aquila, Manuela Dettori, Michele A. Basso, Federica Mazzuca, Maria Alessandra Calegari, Ina Valeria Zurlo, Adele Artemi, Annunziato Anghelone, Emanuela Lucci‐Cordisco, Alessandro Bittoni, Marta Ribelli, Antonella Cosimati, Marta Schirripa, Jessica Lucchetti, Maria Grazia Morandi, Domenico Corsi, Donatello Gemma, Federica Zoratto, Carlo Signorelli, Alessandro Minelli, Giulia Arrivi, Lorenzo Angotti, Fiorenza Santamaria, Alessandra Emiliani, Rosa Saltarelli, Giovanni Luca Frassineti, Alessandro Passardi, Mario Giovanni Chilelli, Cristina Morelli, Emanuela Di Giacomo
article en
2 citations

Abstract

This study suggests that rechallenge therapy may improve survival rates in the third-line treatment of mCRC, particularly if it is administered before sequential R/T treatment. This could allow for the extension of mCRC treatment choices until prospective studies are finished or randomised trials are performed.

Current OncologyVol. 31(12)
University of Rome Tor Vergata (IT), Policlinico Umberto I (IT), Agostino Gemelli University Polyclinic (IT), Accademia di Belle Arti di Frosinone (IT), Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IT), Ospedale San Paolo (IT), Ospedale di Belcolle (IT), Ospedale Santa Maria Goretti (IT), Campus Bio Medico University Hospital (IT), Ospedale Vito Fazzi (IT), Istituti di Ricovero e Cura a Carattere Scientifico (IT), Sapienza University of Rome (IT)
Good health and well-being
Openalex Percentile: Top 26%
Colorectal Cancer Treatments and Studies
0.57
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.